These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19484334)

  • 1. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
    Nussenzveig RH; Cortes J; Sever M; Quintás-Cardama A; Ault P; Manshouri T; Bueso-Ramos C; Prchal JT; Kantarjian H; Verstovsek S
    Int J Hematol; 2009 Jul; 90(1):58-63. PubMed ID: 19484334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
    Merx K; Fabarius A; Erben P; Griesshammer M; Reiter A; Hofmann WK; Hehlmann R; Hochhaus A; Lengfelder E
    Ann Hematol; 2013 Jul; 92(7):907-15. PubMed ID: 23525684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II open label trial of imatinib in polycythemia rubra vera.
    Jones CM; Dickinson TM; Salvado A
    Int J Hematol; 2008 Dec; 88(5):489-494. PubMed ID: 19009241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
    Jones AV; Silver RT; Waghorn K; Curtis C; Kreil S; Zoi K; Hochhaus A; Oscier D; Metzgeroth G; Lengfelder E; Reiter A; Chase AJ; Cross NC
    Blood; 2006 Apr; 107(8):3339-41. PubMed ID: 16352805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.
    Silver RT
    Curr Hematol Malig Rep; 2007 Feb; 2(1):43-6. PubMed ID: 20425387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy].
    Marie I; Hervé F
    Rev Med Interne; 2006 Jun; 27(6):473-7. PubMed ID: 16631280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
    Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
    Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of c-Kit gene mutations in patients with polycythemia vera.
    Fontalba A; Real PJ; Fernandez-Luna JL; Agirre X; Prosper F; Richard C
    Leuk Res; 2006 Oct; 30(10):1325-6. PubMed ID: 16460801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro.
    Oehler L; Jaeger E; Eser A; Sillaber C; Gisslinger H; Geissler K
    Blood; 2003 Sep; 102(6):2240-2. PubMed ID: 12763928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
    Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
    Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
    Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
    Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
    Silver RT
    Curr Hematol Rep; 2005 May; 4(3):235-7. PubMed ID: 15865878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
    Nishida T; Tsukazaki K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():250-5. PubMed ID: 25831762
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
    Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
    Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.